You are here:
denosumab (Prolia)
Advice
In the absence of a submission from the holder of the marketing authorisation:
denosumab 60mg solution for injection in pre-filled syringe (Prolia): Is not recommended for use in NHSScotland.
Indication under review: bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Drug Details
| Drug Name: | denosumab (Prolia) |
|---|---|
| SMC Drug ID: | 670/10 |
| Manufacturer: | Amgen Ltd |
| Indication: | Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures |
| BNF Category: | |
| Sub Category: | 6.6 Drugs affecting bone metabolism |
| Submission Type: | Non submission |
| Status: | Not Recommended |
| Date Advice Published: | 13 December 2010 |